Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Denosumab Clear all
Completed Phase 2 Interventional Results available

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380
View directory record Official record
Conditions
Osteoporosis
Interventions
denosumab, teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

NCT02176382
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
denosumab, teriparatide, Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Early Phase 1 Interventional

Presurgical Trial of Denosumab in Breast Cancer

NCT02900469
View directory record Official record
Conditions
Breast Cancer
Interventions
denosumab, Surgery
Biological · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 22, 2026, 2:29 AM EDT
Terminated Phase 3 Interventional Results available

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

NCT02352753
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02470091
View directory record Official record
Conditions
Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7
Interventions
Denosumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
11 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
132
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657
View directory record Official record
Conditions
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Interventions
Romosozumab, Denosumab, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

NCT03925532
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
Interventions
Denosumab
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 22, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

NCT07043608
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
Interventions
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan
Drug · Radiation · Procedure
Lead sponsor
Kelly Fitzgerald, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 22, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

NCT03029442
View directory record Official record
Conditions
Secondary Osteoporosis, Spinal Cord Injury
Interventions
Denosumab (Prolia), Placebo (normal saline)
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Denosumab
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

NCT00838201
View directory record Official record
Conditions
Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

NCT01464931
View directory record Official record
Conditions
Renal Impairment
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Tempe, Arizona • Denver, Colorado • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

NCT02053753
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Denosumab CP4, Denosumab CP2
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

NCT04087096
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bone Loss
Interventions
Denosumab, Placebo, Zoledronic Acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

NCT05087030
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
RGB-14-P, Prolia®
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 22, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

NCT03960554
View directory record Official record
Conditions
Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions
Denosumab Inj 60 mg/ml, Placebo
Drug · Other
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 22, 2026, 2:29 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
GP2411, EU-Prolia (EU-authorized Prolia®)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

NCT03396315
View directory record Official record
Conditions
IOP, Osteoporosis
Interventions
Alendronate, Zoledronic Acid
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Denosumab on Cellular Biomarkers in the Human Breast

NCT02099461
View directory record Official record
Conditions
Healthy Volunteer, Female, Breast
Interventions
Denosumab, Percutaneous core needle breast biopsy
Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Cypress, California • Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

NCT00680992
View directory record Official record
Conditions
Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
11
States / cities
Santa Monica, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 22, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 22, 2026, 2:29 AM EDT